In that same study, Edbrooke and coworkers found that the absolute expenses to ICU staff rose by 1.3% in only one year (1994 1995 to 1995 1996).
H1: Biopharmaceutical companies with higher absolute R&D expense will have higher performance in terms of growth in revenues, net income, valuation, and Price-Earning (PE) multiples relative to peer competitors.
Table 4 Hypothesis testing results Hypotheses Results H1: Biopharmaceutical companies with higher absolute R&D expense will have higher performance in terms of growth in revenues, net income, valuation, and Price-Earning (PE) multiples relative to peer competitors.
Thus, using an effectuation lens, we pose the following hypotheses in the context of the large multinational biopharmaceutical companies: H1: Biopharmaceutical companies with higher absolute R&D expense will have higher performance in terms of growth in revenues, net income, valuation, and Price-Earning (PE) multiples relative to peer competitors.
CCA was conducted using the three input variables (R&D expenses in absolute dollars ; R&D expenses as percent of revenues; pipelines valuation as percent of total valuation) as predictors of the four performance variables (i.e., revenues, market valuation, net income, price-earning ratio) to evaluate the multivariate-shared relationship between the two variable sets.
It's a radical step, but one that pays a number of dividends: reduced touring expenses, absolute creative autonomy and live shows that compress all the wonder and virtuosity of an illusionist's routine into a three-and-a-half-minute pop song.
Absolute and relative expenses (including costs caused by false-positive results) of each staging method were summarised (Table 3-wrap>).
But wherever compromise tried to sneak in at the expense of absolute quality, we tried to resist it.
Thus, the independent and dependent variables are operationalized as seen in Table 2: Relative to DCF NPV analysis (DiMasi, 2013; Nickisch and Bode-Greuel, 2013), we explore a broader effectuation framework to consider the relative magnitude and intensity of R&D (i.e., R&D expense in absolute dollars and as a percent of revenues, pipeline valuation) over time.
But for this example one can make coordinate changes near each of the points of zero slope to make the slope greater than 1 in absolute value, at the expense only of introducing infinite slope at the pre-images of the critical points as in Fig. 12.
In this case, biopharmaceutical companies with higher absolute and relative R&D expense levels were found to have higher performance in terms of growth in revenues, net income, valuation, and Price-Earning (PE) multiples relative to peer competitors.
